Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06550583

Screening for Early Cervical Cancer Detection

A Clinical Audit on Screening Program for Early Cervical Cancer Detection.

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
Female
Age
20 Years – 60 Years
Healthy volunteers

Summary

This study is to audit results and adherence to Cervical Screening program before and after the implementing awareness of the WHO guidelines of screening among the multidisciplinary healthcare workers and patients.

Detailed description

Cervical cancer screening is the asymptomatic detection of pre-cancer and cancer in women at risk, with at least one screening suggested for women aged 30-49 years. According to the World Health Survey (2015), 19% of eligible women in developing countries and 63% of those in developed nations had their cervical cancer screening done using a Pap smear or visual inspection with acetic acid (VIA). According to latest estimates by World Health Organization (WHO), in Egypt, 866 women are diagnosed with cervical cancer every year and 373 die from the disease. Cervical cancer is the 13th most common cancer in women in Egypt and the 10th most common cancer in women aged between 15 to 44 years . Statistics from Egyptian studies provide pre invasive cervical lesion incidence levels of 0.3 % to 0.5 % . The human papillomavirus (HPV) is one of the most significant risk factors for cervical cancer. HPV can be transmitted through sexual contact, including vaginal or oral sex with an infected person. HPV has more than 100 strains, of which HPV16 and HPV18 account for about 70% of invasive cervical cancers

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTPap smear /TestPatients will be placed in the lithotomy position, and a sterile bivalve speculum will be inserted into the vagina. • A sample will be taken from the ectocervix by rotating a wooden Ayre spatula 360°. The sample will be quickly smeared onto a labeled glass slide and fixed with 95% ethyl alcohol in a jar to be sent to the Department of Pathology for cytopathological examination

Timeline

Start date
2023-06-01
Primary completion
2024-08-30
Completion
2024-09-30
First posted
2024-08-13
Last updated
2024-08-13

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT06550583. Inclusion in this directory is not an endorsement.